Benefits
Fasting blood glucose (generic cinnamon, inconsistent, mostly in diabetics)
The often-quoted 18 to 29 percent fasting-glucose reductions come from a single 40-day trial in 60 people with type 2 diabetes (Khan 2003), which later, larger trials did not reproduce and which now carries a formal Expression of Concern from the journal that published it. Meta-analyses of generic cinnamon are mixed: some report small fasting-glucose reductions in diabetics, others find no significant effect. No study has tested the FenuMat combination or shown effects at the 120 to 500 mg extract dose.
Triglyceride and cholesterol changes (single unreplicated trial)
The triglyceride (23 to 30 percent), LDL (7 to 27 percent) and total-cholesterol (12 to 26 percent) reductions come from one 40-day trial in 60 people with type 2 diabetes (Khan 2003), not from pooled class evidence, and that trial now carries a journal Expression of Concern. These lipid effects have not been reliably reproduced, and no lipid trial exists for the FenuMat combination.
Post-prandial glucose suppression
Cinnamon has documented acute effects on post-prandial blood glucose responses — flattening the glycemic curve after meals via α-amylase and α-glucosidase enzyme inhibition (an acarbose-like mechanism). Effect particularly valuable for adults with normal fasting glucose but elevated post-meal glucose responses — an early sign of metabolic dysfunction.
Insulin sensitivity enhancement
Cinnamon is purported to be a natural insulin sensitizer — supported by both in vitro and animal studies. Mechanism involves insulin receptor auto-phosphorylation/de-phosphorylation, GLUT-4 receptor synthesis and translocation, and modulation of hepatic glucose metabolism via Pyruvate kinase and PEPCK. Multiple pathway effects support sustained glycemic control.
FenuMat® delivery format (not a proven benefit)
FenuMat is a fenugreek soluble-fiber hydrogel used as a delivery format across Akay's portfolio. It is a formulation feature, not a health benefit: no published human study has measured whether it raises absorption of cinnamon compounds or allows lower effective doses than raw cinnamon powder.
Fenugreek glucose-lowering (component tested alone, not combined)
Fenugreek, the FenuMat scaffold component, has its own trial evidence for lowering fasting glucose and HbA1c in people with type 2 diabetes, attributed to 4-hydroxyisoleucine and soluble fiber. That evidence is for fenugreek taken on its own. No study has tested fenugreek combined with cinnamon, so any added or synergistic benefit from the combination is unproven.
Reduced coumarin exposure concerns
Standardized cinnamon extract reduces coumarin exposure vs raw cinnamon powder. EFSA's coumarin limit is 0.1 mg per kg body weight per day (~7 mg/day for a 70 kg adult). Cassia cinnamon powder can contain higher coumarin levels — standardized extracts with lower coumarin support safer long-term daily use vs spice-level dosing concerns.
Mechanism of action
α-Amylase and α-glucosidase inhibition
Cinnamon inhibits intestinal α-amylase and α-glucosidase enzymes — the same target as the pharmaceutical diabetes drug acarbose. These enzymes break down dietary starches and disaccharides into absorbable glucose. Inhibition slows carbohydrate digestion and blunts post-prandial glucose spikes. Mechanism explains the acute post-meal glucose effects.
GLUT-4 receptor synthesis and translocation
GLUT-4 is the insulin-responsive glucose transporter that moves from intracellular vesicles to the cell membrane upon insulin signaling, enabling glucose uptake into muscle and fat cells. Cinnamon supports GLUT-4 receptor synthesis and translocation — enhancing glucose uptake even at the same insulin levels. Mechanism contributes to the insulin sensitivity effects.
Insulin receptor phosphorylation modulation
Cinnamon modulates insulin receptor auto-phosphorylation and de-phosphorylation — improving the receptor's insulin signaling fidelity. The mechanism addresses one of the fundamental defects in type 2 diabetes (insulin receptor dysfunction) rather than just compensating with higher insulin levels.
PPAR-γ expression modulation
Cinnamon alters PPAR-γ (peroxisome proliferator-activated receptor gamma) expression — a transcription factor involved in lipid metabolism, glucose homeostasis, and inflammation. PPAR-γ is also the target of the pharmaceutical diabetes drug class thiazolidinediones (pioglitazone, rosiglitazone). Cinnamon provides milder PPAR-γ modulation.
Hepatic glucose metabolism modulation
Cinnamon modulates hepatic glucose metabolism through changes in Pyruvate kinase (PK) and Phosphoenol Pyruvate Carboxykinase (PEPCK) — key enzymes regulating glucose production by the liver. Hepatic glucose production (gluconeogenesis) is elevated in diabetes; reducing it supports better fasting glucose control.
Clinical trials
Pioneering clinical trial evaluating Cinnamomum cassia at three doses (1, 3, or 6 g/day) for 40 days in subjects with type 2 diabetes. Foundational evidence for cinnamon's glycemic effects. in Diabetes Care (Khan et al.) — one of the most-cited cinnamon trials.
60 Pakistani participants with type 2 diabetes. 40-day intervention with three dose-comparison groups.
Significant reductions in fasting blood sugar at all three doses (18-29%), with greater reduction at higher doses. Cholesterol (including LDL) reduced 7-27%. Triglycerides reduced 23-30%. Total cholesterol reduced 12-26%. This trial is the source of the large glucose and lipid numbers often quoted for cinnamon, but later and larger trials did not reproduce them, and in September 2025 Diabetes Care issued a formal Expression of Concern about it. Limitations: single small trial in 60 Pakistani adults, no HbA1c, results not replicated, now under journal Expression of Concern.
Randomized crossover trial in people with type 2 diabetes testing whether a single 3 g or 6 g dose of raw cinnamon, taken dissolved in water or in gelatin capsules, blunted the glucose rise after a standardized 50 g carbohydrate meal (Moreira 2024, PLoS One).
19 adults with type 2 diabetes. Randomized crossover, 3 g and 6 g raw cinnamon, either dissolved in water or in gelatin capsules, before a standardized meal.
Raw cinnamon dissolved in water decreased meal-induced large glucose spikes (peak-rise of +87 mg/dL and Δ1-hour glycemia of +79 mg/dL) and the hyperglycemic blood glucose peak. Effects via α-amylase/α-glucosidase inhibition (acarbose-like mechanism). When the same cinnamon was given in gelatin capsules instead of dissolved in water, the glucose effect was lost or much smaller. The study did not test FenuMat and says nothing about it; if anything, it shows that encapsulating cinnamon can reduce its acute effect.
Class evidence from multiple pooled analyses of cinnamon clinical trials. Pooled analyses examining glycemic control (fasting glucose, HbA1c, post-prandial glucose) and lipid profile across dozens of cinnamon trials. Provides broad evidence base for metabolic applications.
Various — adults across multiple cinnamon trials in pre-diabetic, type 2 diabetic, and metabolic syndrome populations.
Meta-analyses of generic cinnamon disagree. One (Akilen 2012, 6 RCTs) found a small fasting-glucose reduction and only a very small HbA1c change; another (Mandal 2021, cassia bark) found no significant reduction in glucose or lipids at all. Effects, where present, are modest and inconsistent, and none of these pooled trials tested the FenuMat combination.